Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pazopanib - GlaxoSmithKline/Novartis

Drug Profile

Pazopanib - GlaxoSmithKline/Novartis

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Charite - Universitatsmedizin Berlin; Duke University Medical Center; GlaxoSmithKline; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Comprehensive Cancer Network; Northwestern University; Novartis; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California at Irvine; University of Heidelberg; University of Minnesota; University of Oxford; University of Washington; Washington University School of Medicine
  • Class Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Sarcoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioma; Haemangiosarcoma; Liposarcoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I Head and neck cancer
  • No development reported Colorectal cancer; Liver cancer
  • Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

Most Recent Events

  • 12 Sep 2019 The National Cancer Institute completes a phase II trial for Glioma (Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT01931098)
  • 01 Jan 2019 GlaxoSmithKline completes a phase II trial in Thyroid cancer (Second-line therapy or greater,Treatment-resistant) in France (PO) (NCT01813136)
  • 19 Oct 2018 Safety and efficacy data from a phase Ib/II trial in Ovarian cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top